Skip Nav

Contact Us

Chondrosarcoma CS Foundation, Inc.

Thank you for your interest in our company. Complete the form below to send us an email, or simply give us a call. We're looking forward to working with you.

  • 301-352-3042

    Thank You!

    Your message has been sent.

    Oops, message not sent.

    Please make sure fields are complete.

    News

    NORD Named an Official Charity Partner of the 2021 TCS New York City Marathon


    ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌…

    Read Article

    Virtual Dialogue 3: Taking Charge of Your Care


    Chondrosarcoma CS Foundation, Inc. Virtual Dialogue 3: Taking Charge of Your Care Third International Virtual Dialogue (VIA Zoom) Tuesday, September 14, 2021 7:30PM – 9:00PM (Eastern Standard Time / New York) Join Us for This Very Informative…

    Read Article

    Bone Cancer Research Trust promotes Sarcoma Awareness Month


    This #SarcomaAwareness Month, please help raise awareness of the symptoms of bone sarcoma by liking and sharing our graphic below. Symptoms of bone sarcoma / primary bone cancer can be very general and often appear similar to the symptoms of sports…

    Read Article

    Message from Shayna Kramer on Sarcoma Awareness Month


    Listed below is a message sent by my late daughter Shayna two years ago (July 2, 2019) to promote Sarcoma Awareness Month. Yesterday was the first day of Sarcoma Awareness Month. As someone that is currently fighting a sarcoma I can say that my…

    Read Article

    Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study and Announces Amended Loan Agreement with Oxford


    Published: Jun 21, 2021 SAN DIEGO, June 21, 2021 /PRNewswire/ — InhibRx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, announced initiation of a potential registration-enabling Phase 2 study of INBRX-109…

    Read Article

    Testing the Combination of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma


    SUMMARY This phase II trial studies the effect of belinostat and SGI-110 (guadecitabine) combination therapy in treating patients with conventional chondrosarcoma that cannot be removed by surgery (unresectable) and has spread to other places in…

    Read Article

    Empowering Patients to Speak Up for Your Health


    Check out the video hosted by Memorial Sloan Kettering entitled: Empowering Patients: Speak Up for Your Health. The Empowered Patient: Speak Up for Your Health | Memorial Sloan Kettering Cancer Center (mskcc.org) Transcript: Barbra Rothschild:…

    Read Article

    Article on Targeted Cancer Therapies


    Targeted Cancer Therapies ON THIS PAGE What are targeted cancer therapies? How are targets for targeted cancer therapies identified? How are targeted therapies developed? What types of targeted therapies are available? …

    Read Article

    Contact Information


    If you would like to learn more about CS Foundation or if you would like to learn more about the resources we provide to patients, families, caregivers, and physicians, please contact us by phone or send us a message.

    **A Registered 501c3 Non-Profit Charity Organization. All donations are tax-deductible.**

    Send a Message